Emerging opportunistic yeast infections

The Lancet Infectious Diseases

Volumn 11, Issue 2, 2011, Pages 142-151

  Miceli, Marisa H ^a   Díaz, José A ^b   Lee, Samuel A ^c,d  

^a OAKWOOD HOSPITAL AND MEDICAL CENTER   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^d NEW MEXICO VA HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN; ANTIFUNGAL AGENT; BETA 1,3 GLUCAN; ECHINOCANDIN; GAMMA INTERFERON; IMMUNOMODULATING AGENT; PYRROLE;

BLOOD CULTURE; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CATHETER INFECTION; CRYPTOCOCCOSIS; CRYPTOCOCCUS; FUNGEMIA; GEOTRICHUM; HEMATOLOGIC MALIGNANCY; HOST; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; IMMUNE STATUS; MALASSEZIA; MYCOSIS; NONHUMAN; OPPORTUNISTIC INFECTION; PICHIA; PRIORITY JOURNAL; REVIEW; RHODOTORULA; SACCHAROMYCES; SYSTEMIC MYCOSIS; TRICHOSPORON; YEAST;

BETA-GLUCANS; CLINICAL LABORATORY TECHNIQUES; COMMUNICABLE DISEASES, EMERGING; FUNGI; HUMANS; IMMUNOCOMPROMISED HOST; INCIDENCE; MYCOLOGY; MYCOSES; OPPORTUNISTIC INFECTIONS;

EID: 78751683832     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(10)70218-8     Document Type: Review

References (110)

1. Horn DL, Neofytos D, Anaissie EJ, et al. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis 2009, 48:1695-1703.
2. Ruhnke M Epidemiology of Candida albicans infections and role of non-Candida-albicans yeasts. Curr Drug Targets 2006, 7:495-504.
3. Riedel DJ, Johnson JK, Forrest GN Rhodotorula glutinis fungemia in a liver-kidney transplant patient. Transpl Infect Dis 2008, 10:197-200.
4. Kontoyiannis DP, Torres HA, Chagua M, et al. Trichosporonosis in a tertiary care cancer center: risk factors, changing spectrum and determinants of outcome. Scand J Infect Dis 2004, 36:564-569.
5. Munoz P, Bouza E, Cuenca-Estrella M, et al. Saccharomyces cerevisiae fungemia: an emerging infectious disease. Clin Infect Dis 2005, 40:1625-1634.
6. Girmenia C, Pagano L, Martino B, et al. Invasive infections caused by Trichosporon species and Geotrichum capitatum in patients with hematological malignancies: a retrospective multicenter study from Italy and review of the literature. J Clin Microbiol 2005, 43:1818-1828.
7. Borman AM, Petch R, Linton CJ, Palmer MD, Bridge PD, Johnson EM Candida nivariensis, an emerging pathogenic fungus with multidrug resistance to antifungal agents. J Clin Microbiol 2008, 46:933-938.
8. Snydman DR Shifting patterns in the epidemiology of nosocomial Candida infections. Chest 2003, 123(suppl):500S-503S.
9. Pfaller MA, Diekema DJ, Gibbs DL, et al. Results from the ARTEMIS DISK global antifungal surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J Clin Microbiol 2007, 45:1735-1745.
10. Tan TY, Tan AL, Tee NW, Ng LS, Chee CW The increased role of non-albicans species in candidaemia: results from a 3-year surveillance study. Mycoses 2009, published online July 10. 10.1111/j.1439-0507.2009.01746.x.
11. Colombo AL, Nucci M, Park BJ, et al. Epidemiology of candidemia in Brazil: a nationwide sentinel surveillance of candidemia in eleven medical centers. J Clin Microbiol 2006, 44:2816-2823.
12. Chen S, Slavin M, Nguyen Q, et al. Active surveillance for candidemia, Australia. Emerg Infect Dis 2006, 12:1508-1516.
13. Trofa D, Gacser A, Nosanchuk JD Candida parapsilosis, an emerging fungal pathogen. Clin Microbiol Rev 2008, 21:606-625.
14. Chen SC, Marriott D, Playford EG, et al. Candidaemia with uncommon Candida species: predisposing factors, outcome, antifungal susceptibility, and implications for management. Clin Microbiol Infect 2009, 15:662-669.
15. Sendid B, Lacroix C, Bougnoux ME Is Candida kefyr an emerging pathogen in patients with oncohematological diseases?. Clin Infect Dis 2006, 43:666-667.
16. Mestroni SC, Verna JA, Smolkin A, Bava AJ Etiological factors of fungemia in the Hospital San Martin in La Plata. Rev Argent Microbiol 2003, 35:106-109.
17. Minces LR, Ho KS, Veldkamp PJ, Clancy CJ Candida rugosa: a distinctive emerging cause of candidaemia. A case report and review of the literature. Scand J Infect Dis 2009, 41:892-897.
18. Trifilio S, Singhal S, Williams S, et al. Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. Bone Marrow Transplant 2007, 40:451-456.
19. Leung AY, Chim CS, Ho PL, et al. Candida tropicalis fungaemia in adult patients with haematological malignancies: clinical features and risk factors. J Hosp Infect 2002, 50:316-319.
20. Pfaller MA, Diekema DJ, Gibbs DL, et al. Results from the ARTEMIS DISK global antifungal surveillance study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida species to fluconazole and voriconazole determined by CLSI standardized disk diffusion. J Clin Microbiol 2007, 45:1735-1745.
21. Reuter CW, Morgan MA, Bange FC, et al. Candida kefyr as an emerging pathogen causing nosocomial bloodstream infections in neutropenic leukemia patients. Clin Infect Dis 2005, 41:1365-1366.
22. Tavanti A, Davidson AD, Gow NA, Maiden MC, Odds FC Candida orthopsilosis and Candida metapsilosis spp. nov. to replace Candida parapsilosis groups II and III. J Clin Microbiol 2005, 43:284-292.
23. Linton CJ, Borman AM, Cheung G, et al. Molecular identification of unusual pathogenic yeast isolates by large ribosomal subunit gene sequencing: 2 years of experience at the United Kingdom mycology reference laboratory. J Clin Microbiol 2007, 45:1152-1158.
24. Lachance MA, Starmer WT, Rosa CA, Bowles JM, Barker JS, Janzen DH Biogeography of the yeasts of ephemeral flowers and their insects. FEMS Yeast Res 2001, 1:1-8.
25. Ramage G, Saville SP, Thomas DP, Lopez-Ribot JL Candida biofilms: an update. Eukaryot Cell 2005, 4:633-638.
26. Silva S, Henriques M, Martins A, Oliveira R, Williams D, Azeredo J Biofilms of non-Candida albicans Candida species: quantification, structure and matrix composition. Med Mycol 2009, 47:681-689.
27. Pfaller MA, Diekema DJ, Mendez M, et al. Candida guilliermondii, an opportunistic fungal pathogen with decreased susceptibility to fluconazole: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program. J Clin Microbiol 2006, 44:3551-3556.
28. Pfaller MA, Diekema DJ, Colombo AL, et al. Candida rugosa, an emerging fungal pathogen with resistance to azoles: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program. J Clin Microbiol 2006, 44:3578-3582.
29. Hawkins JL, Baddour LM Candida lusitaniae infections in the era of fluconazole availability. Clin Infect Dis 2003, 36:e14-e18.
30. Martinez M, Lopez-Ribot JL, Kirkpatrick WR, Coco BJ, Bachmann SP, Patterson TF Replacement of Candida albicans with C. dubliniensis in human immunodeficiency virus-infected patients with oropharyngeal candidiasis treated with fluconazole. J Clin Microbiol 2002, 40:3135-3139.
31. Pfaller MA, Boyken L, Hollis RJ, Messer SA, Tendolkar S, Diekema DJ In vitro susceptibilities of Candida spp. to caspofungin: four years of global surveillance. J Clin Microbiol 2006, 44:760-763.
32. Garcia-Efron G, Park S, Lee S, Perlin DS. Echinocandin resistance in clinical Candida spp. isolates. 47th Interscience Conference Antimicrobial Agents and Chemotherapy; Sept 17-20, 2007; Chicago, IL, USA; 2007: M-2017.
33. Sun HY, Singh N Characterisation of breakthrough invasive mycoses in echinocandin recipients: an evidence-based review. Int J Antimicrob Agents 2010, 35:211-218.
34. Moudgal V, Little T, Boikov D, Vazquez JA Multiechinocandin- and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis. Antimicrob Agents Chemother 2005, 49:767-769.
35. Mermel LA, Farr BM, Sherertz RJ, et al. Guidelines for the management of intravascular catheter-related infections. Clin Infect Dis 2001, 32:1249-1272.
36. Flemming RV, Walsh TJ, Anaissie EJ Emerging and less common fungal pathogens. Infect Dis Clin North Am 2002, 16:915-933.
37. Melcher GP, Reed KD, Rinaldi MG, Lee JW, Pizzo PA, Walsh TJ Demonstration of a cell wall antigen cross-reacting with cryptococcal polysaccharide in experimental disseminated trichosporonosis. J Clin Microbiol 1991, 29:192-196.
38. Ando M, Suga M, Nishiura Y, Miyajima M Summer-type hypersensitivity pneumonitis. Intern Med 1995, 34:707-712.
39. Ruan SY, Chien JY, Hsueh PR Invasive trichosporonosis caused by Trichosporon asahii and other unusual Trichosporon species at a medical center in Taiwan. Clin Infect Dis 2009, 49:e11-e17.
40. Walsh TJ, Groll A, Hiemenz J, Fleming R, Roilides E, Anaissie E Infections due to emerging and uncommon medically important fungal pathogens. Clin Microbiol Infect 2004, 10(suppl 1):48-66.
41. Pfaller MA, Diekema DJ Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus. J Clin Microbiol 2004, 42:4419-4431.
42. Denning DW Echinocandin antifungal drugs. Lancet 2003, 362:1142-1151.
43. Ribeiro M Araujo, Alastruey-Izquierdo A, Gomez-Lopez A, Rodriguez-Tudela JL, Cuenca-Estrella M Molecular identification and susceptibility testing of Trichosporon isolates from a Brazilian hospital. Rev Iberoam Micol 2008, 25:221-225.
44. Suzuki K, Nakase K, Kyo T, et al. Fatal Trichosporon fungemia in patients with hematologic malignancies. Eur J Haematol 2010, 84:441-447.
45. Tuon FF, Costa SF Rhodotorula infection. A systematic review of 128 cases from literature. Rev Iberoam Micol 2008, 25:135-140.
46. Tournas VH, Katsoudas E, Miracco EJ Moulds, yeasts and aerobic plate counts in ginseng supplements. Int J Food Microbiol 2006, 108:178-181.
47. Tournas VH, Heeres J, Burgess L Moulds and yeasts in fruit salads and fruit juices. Food Microbiol 2006, 23:684-688.
48. Perniola R, Faneschi ML, Manso E, et al. Rhodotorula mucilaginosa outbreak in neonatal intensive care unit: microbiological features, clinical presentation, and analysis of related variables. Eur J Clin Microbiol Infect Dis 2006, 25:193-196.
49. Lunardi LW, Aquino VR, Zimerman RA, Goldani LZ Epidemiology and outcome of Rhodotorula fungemia in a tertiary care hospital. Clin Infect Dis 2006, 43:e60-e63.
50. Braun DK, Kauffman CA Rhodotorula fungaemia: a life-threatening complication of indwelling central venous catheters. Mycoses 1992, 35:305-308.
51. Diekema DJ, Petroelje B, Messer SA, Hollis RJ, Pfaller MA Activities of available and investigational antifungal agents against rhodotorula species. J Clin Microbiol 2005, 43:476-478.
52. Zaas AK, Boyce M, Schell W, Lodge BA, Miller JL, Perfect JR Risk of fungemia due to Rhodotorula and antifungal susceptibility testing of Rhodotorula isolates. J Clin Microbiol 2003, 41:5233-5235.
53. Khawcharoenporn T, Apisarnthanarak A, Mundy LM Non-neoformans cryptococcal infections: a systematic review. Infection 2007, 35:51-58.
54. Shankar EM, Kumarasamy N, Bella D, et al. Pneumonia and pleural effusion due to Cryptococcus laurentii in a clinically proven case of AIDS. Can Respir J 2006, 13:275-278.
55. Manfredi R, Fulgaro C, Sabbatani S, Legnani G, Fasulo G Emergence of amphotericin B-resistant Cryptococcus laurentii meningoencephalitis shortly after treatment for Cryptococcus neoformans meningitis in a patient with AIDS. AIDS Patient Care STDS 2006, 20:227-232.
56. Lee YA, Kim HJ, Lee TW, et al. First report of Cryptococcus albidus-induced disseminated cryptococcosis in a renal transplant recipient. Korean J Intern Med 2004, 19:53-57.
57. Furman-Kuklinska K, Naumnik B, Mysliwiec M Fungaemia due to Cryptococcus laurentii as a complication of immunosuppressive therapy-a case report. Adv Med Sci 2009, 54:116-119.
58. D'Antonio D, Mazzoni A, Iacone A, et al. Emergence of fluconazole-resistant strains of Blastoschizomyces capitatus causing nosocomial infections in cancer patients. J Clin Microbiol 1996, 34:753-755.
59. Girmenia C, Pizzarelli G, D'Antonio D, Cristini F, Martino P In vitro susceptibility testing of Geotrichum capitatum: comparison of the E-test, disk diffusion, and Sensititre colorimetric methods with the NCCLS M27-A2 broth microdilution reference method. Antimicrob Agents Chemother 2003, 47:3985-3988.
60. Paula CR, Krebs VL, Auler ME, et al. Nosocomial infection in newborns by Pichia anomala in a Brazilian intensive care unit. Med Mycol 2006, 44:479-484.
61. Pasqualotto AC, Sukiennik TC, Severo LC, de Amorim CS, Colombo AL An outbreak of Pichia anomala fungemia in a Brazilian pediatric intensive care unit. Infect Control Hosp Epidemiol 2005, 26:553-558.
62. Kalenic S, Jandrlic M, Vegar V, Zuech N, Sekulic A, Mlinaric-Missoni E Hansenula anomala outbreak at a surgical intensive care unit: a search for risk factors. Eur J Epidemiol 2001, 17:491-496.
63. Thuler LC, Faivichenco S, Velasco E, Martins CA, Nascimento CR, Castilho IA Fungaemia caused by Hansenula anomala-an outbreak in a cancer hospital. Mycoses 1997, 40:193-196.
64. Krcmery V, Oravcova E, Spanik S, et al. Nosocomial breakthrough fungaemia during antifungal prophylaxis or empirical antifungal therapy in 41 cancer patients receiving antineoplastic chemotherapy: analysis of aetiology risk factors and outcome. J Antimicrob Chemother 1998, 41:373-380.
65. Murphy N, Buchanan CR, Damjanovic V, Whitaker R, Hart CA, Cooke RWI Infection and colonisation of neonates by Hansenula anomala. Lancet 1986, 327:291-293.
66. Mackenzie DWR Yeasts from human sources. Sabouraudia 1961, 1:8-15.
67. Bakir M, Cerikcioglu N, Tirtir A, Berrak S, Ozek E, Canpolat C Pichia anomala fungaemia in immunocompromised children. Mycoses 2004, 47:231-235.
68. da Matta VL, de Souza Carvalho Melhem M, Colombo AL, et al. Antifungal drug susceptibility profile of Pichia anomala isolates from patients presenting with nosocomial fungemia. Antimicrob Agents Chemother 2007, 51:1573-1576.
69. Morrison VA, Weisdorf DJ The spectrum of Malassezia infections in the bone marrow transplant population. Bone Marrow Transplant 2000, 26:645-648.
70. Gupta AK, Kohli Y, Li A, Faergemann J, Summerbell RC In vitro susceptibility of the seven Malassezia species to ketoconazole, voriconazole, itraconazole and terbinafine. Br J Dermatol 2000, 142:758-765.
71. Velegraki A, Alexopoulos EC, Kritikou S, Gaitanis G Use of fatty acid RPMI 1640 media for testing susceptibilities of eight Malassezia species to the new triazole posaconazole and to six established antifungal agents by a modified NCCLS M27-A2 microdilution method and Etest. J Clin Microbiol 2004, 42:3589-3593.
72. Cassone M, Serra P, Mondello F, et al. Outbreak of Saccharomyces cerevisiae subtype boulardii fungemia in patients neighboring those treated with a probiotic preparation of the organism. J Clin Microbiol 2003, 41:5340-5343.
73. Swinne D, Watelle M, Van der Flaes M, Nolard N In vitro activities of voriconazole (UK-109, 496), fluconazole, itraconazole and amphotericin B against 132 non-albicans bloodstream yeast isolates (CANARI study). Mycoses 2004, 47:177-183.
74. Tiballi RN, Spiegel JE, Zarins LT, Kauffman CA Saccharomyces cerevisiae infections and antifungal susceptibility studies by colorimetric and broth macrodilution methods. Diagn Microbiol Infect Dis 1995, 23:135-140.
75. Jensen J, Munoz P, Guinea J, Rodriguez-Creixems M, Pelaez T, Bouza E Mixed fungemia: incidence, risk factors, and mortality in a general hospital. Clin Infect Dis 2007, 44:e109-e114.
76. Nace HL, Horn D, Neofytos D Epidemiology and outcome of multiple-species candidemia at a tertiary care center between 2004 and 2007. Diagn Microbiol Infect Dis 2009, 64:289-294.
77. Miceli MH, Maertens J, Buve K, et al. Immune reconstitution inflammatory syndrome in cancer patients with pulmonary aspergillosis recovering from neutropenia: proof of principle, description, and clinical and research implications. Cancer 2007, 110:112-120.
78. Singh N Novel immune regulatory pathways and their role in immune reconstitution syndrome in organ transplant recipients with invasive mycoses. Eur J Clin Microbiol Infect Dis 2008, 27:403-408.
79. Zelante T, De Luca A, Bonifazi P, et al. IL-23 and the Th17 pathway promote inflammation and impair antifungal immune resistance. Eur J Immunol 2007, 37:2695-2706.
80. Zelante T, Montagnoli C, Bozza S, et al. Receptors and pathways in innate antifungal immunity: the implication for tolerance and immunity to fungi. Adv Exp Med Biol 2007, 590:209-221.
81. Shoham S, Levitz SM The immune response to fungal infections. Br J Haematol 2005, 129:569-582.
82. Osterholzer JJ, Milam JE, Chen GH, Toews GB, Huffnagle GB, Olszewski MA Role of dendritic cells and alveolar macrophages in regulating early host defense against pulmonary infection with Cryptococcus neoformans. Infect Immun 2009, 77:3749-3758.
83. Bettelli E, Carrier Y, Gao W, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006, 441:235-238.
84. Stockinger B, Veldhoen M Differentiation and function of Th17 T cells. Curr Opin Immunol 2007, 19:281-286.
85. Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B TGFβ in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 2006, 24:179-189.
86. Zhang Y, Wang F, Tompkins KC, et al. Robust Th1 and Th17 immunity supports pulmonary clearance but cannot prevent systemic dissemination of highly virulent Cryptococcus neoformans H99. Am J Pathol 2009, 175:2489-2500.
87. Singh N, Perfect JR Immune reconstitution syndrome associated with opportunistic mycoses. Lancet Infect Dis 2007, 7:395-401.
88. Kontoyiannis DP, Sumoza D, Tarrand J, Bodey GP, Storey R, Raad II Significance of aspergillemia in patients with cancer: a 10-year study. Clin Infect Dis 2000, 31:188-189.
89. Lundstrom T, Sobel J Nosocomial candiduria: a review. Clin Infect Dis 2001, 32:1602-1607.
90. Pittet D, Monod M, Suter PM, Frenk E, Auckenthaler R Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg 1994, 220:751-758.
91. Jorda-Marcos R, Alvarez-Lerma F, Jurado M, et al. Risk factors for candidaemia in critically ill patients: a prospective surveillance study. Mycoses 2007, 50:302-310.
92. Mennink-Kersten MA, Verweij PE Non-culture-based diagnostics for opportunistic fungi. Infect Dis Clin North Am 2006, 20:711-727.
93. Lee SA, Wong B Advances in diagnostic methods for invasive Candida and Aspergillus infections. The mycota: a comprehensive treatise on fungi as experimental systems for basic and applied research 2004, 37-64. Springer-Verlag, Berlin. J. Domer, G.S. Kobayashi (Eds.).
94. Wheat LJ Approach to the diagnosis of invasive aspergillosis and candidiasis. Clin Chest Med 2009, 30:367-377.
95. Iwanaga S, Miyata T, Tokunaga F, Muta T Molecular mechanism of hemolymph clotting system in Limulus. Thromb Res 1992, 68:1-32.
96. Miyazaki T, Kohno S, Mitsutake K, et al. Plasma (1→3)-beta-D-glucan and fungal antigenemia in patients with candidemia, aspergillosis, and cryptococcosis. J Clin Microbiol 1995, 33:3115-3118.
97. Yoshida M, Obayashi T, Iwama A, et al. Detection of plasma (1→3)-beta-D-glucan in patients with Fusarium, Trichosporon, Saccharomyces and Acremonium fungaemias. J Med Vet Mycol 1997, 35:371-374.
98. Odabasi Z, Paetznick VL, Rodriguez JR, Chen E, McGinnis MR, Ostrosky-Zeichner L Differences in beta-glucan levels in culture supernatants of a variety of fungi. Med Mycol 2006, 44:267-272.
99. Obayashi T, Yoshida M, Mori T, et al. Plasma (1→3)-β-D-glucan measurement in diagnosis of invasive deep mycosis and fungal febrile episodes. Lancet 1995, 345:17-20.
100. Ostrosky-Zeichner L, Alexander BD, Kett DH, et al. Multicenter clinical evaluation of the (1→3) β-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 2005, 41:654-659.
101. Senn L, Robinson JO, Schmidt S, et al. 1,3-β-D-glucan antigenemia for early diagnosis of invasive fungal infections in neutropenic patients with acute leukemia. Clin Infect Dis 2008, 46:878-885.
102. Leon C, Ruiz-Santana S, Saavedra P, et al. Usefulness of the "Candida score" for discriminating between Candida colonization and invasive candidiasis in non-neutropenic critically ill patients: a prospective multicenter study. Crit Care Med 2009, 37:1624-1633.
103. Pickering JW, Sant HW, Bowles CA, Roberts WL, Woods GL Evaluation of a (1→3)-β-D-glucan assay for diagnosis of invasive fungal infections. J Clin Microbiol 2005, 43:5957-5962.
104. Akamatsu N, Sugawara Y, Kaneko J, Tamura S, Makuuchi M Preemptive treatment of fungal infection based on plasma (1→3) β-D-glucan levels after liver transplantation. Infection 2007, 35:346-351.
105. Persat F, Ranque S, Derouin F, Michel-Nguyen A, Picot S, Sulahian A Contribution of the (1→3)-β-D-glucan assay for diagnosis of invasive fungal infections. J Clin Microbiol 2008, 46:1009-1013.
106. Presterl E, Parschalk B, Bauer E, Lassnigg A, Hajdu S, Graninger W Invasive fungal infections and (1,3)-β-D-glucan serum concentrations in long-term intensive care patients. Int J Infect Dis 2009, 13:707-712.
107. Digby J, Kalbfleisch J, Glenn A, Larsen A, Browder W, Williams D Serum glucan levels are not specific for presence of fungal infections in intensive care unit patients. Clin Diagn Lab Immunol 2003, 10:882-885.
108. Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009, 48:503-535.
109. Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of America. Clin Infect Dis 2010, 50:291-322.
110. Nucci M, Anaissie E Revisiting the source of candidemia: skin or gut?. Clin Infect Dis 2001, 33:1959-1967.